-
Product Insights
Rajur (Incl. RO) Mine
The Rajur (Incl. RO) Mine is a coal mine in India. It is currently in operation. Empower your strategies with our Rajur (Incl. RO) Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6382 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6382 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6382 in Systemic Lupus Erythematosus Drug Details: RO-7507062 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6468 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6468 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6468 in Solid Tumor Drug Details: RG-6468 (RO-7566802) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6315 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6315 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6315 in Inflammation Drug Details: RG-6315 (RO-7303509) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Forimtamig in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Forimtamig in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Forimtamig in Refractory Multiple Myeloma Drug Details: Forimtamig (RO-7425781) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6457 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6457 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6457 in Solid Tumor Drug Details: RG-6457 (RO-7589831) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Codrituzumab (RG-7686,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6115 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6115 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6115 in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6115 (RO-7119929)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tobemstomig in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tobemstomig in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tobemstomig in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6139...